Drugs / 68Gallium DOTATATE
68Gallium DOTATATE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04927416 | Oct 2021 → Nov 2030 expected | thyroid gland carcinoma | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT04074135 | Jun 2020 → Jan 2036 expected | pancreatic neuroendocrine tumor, von Hippel-Lindau disease | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT01967537 | Oct 2013 → Dec 2017 | neuroendocrine neoplasm, von Hippel-Lindau disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Gallium-DOTATATE | “NET cells express somatostatin receptors that can be targeted with radiolabeled 68Gallium-DOTATATE (Octreotate) for imaging purposes.” NCT01967537 ↗ |
| Known as | 68Ga-DOTATATE | “68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.” NCT04927416 ↗ |
| Known as | Octreotate | “NET cells express somatostatin receptors that can be targeted with radiolabeled 68Gallium-DOTATATE (Octreotate) for imaging purposes.” NCT01967537 ↗ |
| Modality | Diagnostic / imaging agent | “a new experimental imaging agent, 68Gallium-DOTATATE” NCT01967537 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT01967537 ↗ |